Chen Schor’s Post

Thanking our investors for the vote of confidence in the team, pipeline and our gamma-delta1 CAR T platform. We look forward to making a potentially significant impact on the lives of autoimmune and cancer patients. Adicet Bio, Inc, #celltherapy #CART #autoimmune #innovationforpatients #biotechnology #biotechinnovation #biotechinvesting https://lnkd.in/ei85BqCv

We are seeking a talented physician scientist (M.D., Ph.D) to join us on our mission to deliver potentially curative CAR T therapies for patients with autoimmune diseases. Our clinical data for ADI-001 has shown B-cell depletion that mirrors the B cell depletion by autologous alpha-beta CAR T in academic clinical studies in systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathy patients that demonstrated robust responses. Our ADI-001 is designed to target and deplete B cells in the periphery, secondary lymphoid organs, kidneys, and other organs, which is highly desirable in autoimmune diseases. As we have received FDA clearance for our IND for lupus nephritis, we expect to begin enrollment for the study and expand to additional autoimmune indications. Join us in this incredible endeavor to provide potentially curative CAR T therapies for patients with autoimmune diseases. #AutoimmuneDiseases #CAR-TTherapies #ClinicalStudies #LupusNephritis #MedicalResearch #PhysicianScientist

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) https://lnkd.in/eC5P4qGC

https://lnkd.in/eP6pDX4N

We are looking for a great leader to lead our regulatory team. This is a wonderful opportunity to lead us through our pivotal program with ADI-001 and potential regulatory approvals as well as progress additional pipeline programs into clinical development!

Presence of gamma-delta1 T cells is strongly associated with survival of patients with Non-Small Cell Lung Cancer and several additional solid tumors. Check recent nature cancer publication:

Proud of our Adicet team, and humbled and honored to drive ADI-001 toward potential pivotal studies. it is gratifying to see the positive clinical data for ADI-001 presented at #ASCO22! See full press release here https://lnkd.in/gTAzuS8k